Page 125 - 《中国药房》2023年24期

[ 3 ] GOLDSTRAW P，CHANSKY K，CROWLEY J，et al. 2288-2301.
The IASLC lung cancer staging project：proposals for revi‐ [15] HERBST R S，LOPES G，KOWALSKI D M，et al. LBA4
sion of the TNM stage groupings in the forthcoming association of KRAS mutational status with response to
（eighth）edition of the TNM classification for lung cancer pembrolizumab monotherapy given as first-line therapy
[J]. J Thorac Oncol，2016，11（1）：39-51. for PD-L1-positive advanced non-squamous NSCLC in
[ 4 ] HUDSON K，CROSS N，JORDAN-MAHY N，et al. The keynote-042[J]. Ann Oncol，2019，30：Ⅺ63-Ⅺ64.
extrinsic and intrinsic roles of PD-L1 and its receptor PD- [16] GADGEEL S，RODRIGUEZ-ABREU D，FELIP E，et al.
1：implications for immunotherapy treatment[J]. Front Im‐ KRAS mutational status and efficacy in keynote-189：
munol，2020，11：568931. pembrolizumab（pembro）plus chemotherapy（chemo）vs
[ 5 ] TOPALIAN S L，DRAKE C G，PARDOLL D M. Targeting placebo plus chemo as first-line therapy for metastatic
the PD-1/B7-H1（PD-L1）pathway to activate anti-tumor non-squamous NSCLC[J]. Ann Oncol，2019，30：Ⅺ 64-
immunity[J]. Curr Opin Immunol，2012，24（2）：207-212. Ⅺ65.
[ 6 ] NISHIO M，BARLESI F，WEST H，et al. Atezolizumab [17] RITTMEYER A，BARLESI F，WATERKAMP D，et al.
plus chemotherapy for first-line treatment of nonsqua‐ Atezolizumab versus docetaxel in patients with previously
mous NSCLC：results from the randomized phase 3 IM‐ treated non-small-cell lung cancer（OAK）：a phase 3，
power132 trial[J]. J Thorac Oncol，2021，16（4）：653-664. open-label，multicentre randomised controlled trial[J].
[ 7 ] JOTTE R，CAPPUZZO F，VYNNYCHENKO I，et al. Lancet，2017，389（10066）：255-265.
Atezolizumab in combination with carboplatin and nab- [18] FEHRENBACHER L，SPIRA A，BALLINGER M，et al.
paclitaxel in advanced squamous NSCLC（IMpower131）： Atezolizumab versus docetaxel for patients with pre-
results from a randomized phase Ⅲ trial[J]. J Thorac On‐ viously treated non-small-cell lung cancer（POPLAR）：a
col，2020，15（8）：1351-1360. multicentre，open-label，phase 2 randomised controlled
[ 8 ] BUDAY L，DOWNWARD J. Many faces of ras activation trial[J]. Lancet，2016，387（10030）：1837-1846.
[J]. Biochim Biophys Acta，2008，1786（2）：178-187. [19] IPPOLITO M R，MARTIS V，MARTIN S，et al. Gene
[ 9 ] BOS J L. Ras oncogenes in human cancer：a review[J]. copy-number changes and chromosomal instability in‐
Cancer Res，1989，49（17）：4682-4689. duced by aneuploidy confer resistance to chemotherapy
[10] ADDERLEY H，BLACKHALL F H，LINDSAY C R. [J]. Dev Cell，2021，56（17）：2440-2454.e6.
KRAS-mutant non-small cell lung cancer：converging [20] HARGADON K M，JOHNSON C E，WILLIAMS C J. Im‐
small molecules and immune checkpoint inhibition[J]. mune checkpoint blockade therapy for cancer：an over‐
EBioMedicine，2019，41：711-716. view of FDA-approved immune checkpoint inhibitors[J].
[11] GREEN S，HIGGINS J P. Preparing a cochrane review Int Immunopharmacol，2018，62：29-39.
[M]//Cochrane Handbook for Systematic Reviews of Inter‐ [21] RECK M，CARBONE D P，GARASSINO M，et al. Tar‐
ventions. Chichester，UK：John Wiley & Sons，Ltd.，2008： geting KRAS in non-small-cell lung cancer：recent prog‐
11-30. ress and new approaches[J]. Ann Oncol，2021，32（9）：
[12] BORGHAEI H，PAZ-ARES L，HORN L，et al. Nivo- 1101-1110.
lumab versus docetaxel in advanced nonsquamous non- [22] MASCAUX C，IANNINO N，MARTIN B，et al. The role
small-cell lung cancer[J]. N Engl J Med，2015，373（17）： of RAS oncogene in survival of patients with lung cancer：
1627-1639. a systematic review of the literature with meta-analysis[J].
[13] HELLMANN M D，PAZ-ARES L，BERNABE CARO R， Br J Cancer，2005，92（1）：131-139.
et al. Nivolumab plus ipilimumab in advanced non-small- [23] OSTA B E，BEHERA M，KIM S，et al. Characteristics and
cell lung cancer[J]. N Engl J Med，2019，381（21）：2020- outcomes of patients with metastatic KRAS-mutant lung
2031. adenocarcinomas：the lung cancer mutation consortium ex‐
[14] SOCINSKI M A，JOTTE R M，CAPPUZZO F，et al. perience[J]. J Thorac Oncol，2019，14（5）：876-889.
Atezolizumab for first-line treatment of metastatic non‐ （收稿日期：2023-05-08 修回日期：2023-11-21）
squamous NSCLC[J]. N Engl J Med，2018，378（24）： （编辑：陈 宏）

中国药房 2023年第34卷第24期 China Pharmacy 2023 Vol. 34 No. 24 · 3059 ·